Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsSUBCUTANEOUSStandard

WEGOVY

SEMAGLUTIDE

Standard Dose
0.25MG/0.5ML (0.25MG/0.5ML)
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview WEGOVY is listed in Drugs@FDA under application 215256 (NDA).

Review priority: STANDARD Marketing status: Prescription Active ingredient SEMAGLUTIDE Form and strength SOLUTION;SUBCUTANEOUS - 0.25MG/0.5ML (0.25MG/0.5ML) Sponsor NOVO Submission history Latest submission status date: 2026-03-19 00:00:00.

Structured Monograph

Clinical summary

Approval overview WEGOVY is listed in Drugs@FDA under application 215256 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient SEMAGLUTIDE Form and strength SOLUTION;SUBCUTANEOUS - 0.25MG/0.5ML (0.25MG/0.5ML) Sponsor NOVO Submission history Latest submission status date: 2026-03-19 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.
WEGOVY (SEMAGLUTIDE) | Drug Monograph | MedicHelpline